Millot Frederic, Brizard Francoise, Sorel Nathalie, Preudhomme Claude, Cividin Marie, Guilhot Francois, Brizard Andre
Service d'Oncologie Hématologique et de Thérapie Cellulaire, Universitary Hospital, Poitiers, France.
Leuk Lymphoma. 2005 Jun;46(6):925-7. doi: 10.1080/10428190500052248.
The occurrence of therapy-related acute lymphoblastic leukemia (ALL) is rare and, to our knowledge, is not reported in patients treated for Burkitt's leukemia. We report on a child with ALL with translocation t(4;11)(q21;q23) involving the MLL gene, 13 months after chemotherapy for Burkitt's leukemia. This present observation indicates that caution should be exercised in using high cumulative doses of DNA topoisomerase II inhibitors in such patients.
治疗相关的急性淋巴细胞白血病（ALL）的发生较为罕见，据我们所知，在接受伯基特白血病治疗的患者中尚未见报道。我们报告了一名患有ALL且发生涉及MLL基因的t(4;11)(q21;q23)易位的儿童，该患儿在接受伯基特白血病化疗13个月后发病。目前的这一观察结果表明，在此类患者中使用高累积剂量的DNA拓扑异构酶II抑制剂时应谨慎。
